Bio-Rad Laboratories (BIO) Cash & Equivalents (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash & Equivalents for 18 consecutive years, with $517.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 39.99% year-over-year to $517.0 million in Q2 2026; TTM through Jun 2026 was $517.0 million, a 39.99% increase from a year earlier, with the FY2025 full-year figure at $529.8 million, up 8.54% from the prior year.
• Cash & Equivalents was $517.0 million for Q2 2026 at Bio-Rad Laboratories, up from $507.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $802.3 million in Q1 2022 and troughed at $369.3 million in Q2 2025.
• A 5-year average of $480.3 million and a median of $461.0 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 42.15% in 2023 and surged 39.99% in 2026, its largest moves.
• Over 5 years, Cash & Equivalents stood at $434.2 million in 2022, then declined by 7.0% to $403.8 million in 2023, then grew by 20.88% to $488.1 million in 2024, then increased by 8.54% to $529.8 million in 2025, then slipped by 2.42% to $517.0 million in 2026.
• The last three Cash & Equivalents figures came in at $517.0 million (Q2 2026), $507.2 million (Q1 2026), and $529.8 million (Q4 2025), per Business Quant data.